Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 1
1953 2
1954 1
1955 1
1956 2
1957 1
1958 1
1961 3
1962 2
1963 1
1966 1
1967 3
1969 3
1970 6
1971 2
1972 1
1974 1
1976 1
1977 1
1978 4
1979 1
1980 7
1981 3
1982 2
1983 5
1984 6
1985 8
1986 6
1987 9
1988 3
1989 4
1990 12
1991 10
1992 5
1993 13
1994 11
1995 11
1996 12
1997 15
1998 8
1999 21
2000 16
2001 19
2002 21
2003 21
2004 20
2005 28
2006 24
2007 30
2008 23
2009 26
2010 33
2011 28
2012 41
2013 33
2014 23
2015 24
2016 36
2017 44
2018 46
2019 45
2020 59
2021 65
2022 73
2023 68
2024 35

Text availability

Article attribute

Article type

Publication date

Search Results

969 results

Results by year

Filters applied: . Clear all
Page 1
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.
Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Kopyltsov E, Méndez-Vidal MJ, Kozlov V, Alyasova A, Hong SH, Kapoor A, Alonso Gordoa T, Merchan JR, Winquist E, Maroto P, Goh JC, Kim M, Gurney H, Patel V, Peer A, Procopio G, Takagi T, Melichar B, Rolland F, De Giorgi U, Wong S, Bedke J, Schmidinger M, Dutcus CE, Smith AD, Dutta L, Mody K, Perini RF, Xing D, Choueiri TK; CLEAR Trial Investigators. Motzer R, et al. Among authors: eto m. N Engl J Med. 2021 Apr 8;384(14):1289-1300. doi: 10.1056/NEJMoa2035716. Epub 2021 Feb 13. N Engl J Med. 2021. PMID: 33616314 Clinical Trial.
Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study.
Choueiri TK, Eto M, Motzer R, De Giorgi U, Buchler T, Basappa NS, Méndez-Vidal MJ, Tjulandin S, Hoon Park S, Melichar B, Hutson T, Alemany C, McGregor B, Powles T, Grünwald V, Alekseev B, Rha SY, Kopyltsov E, Kapoor A, Alonso Gordoa T, Goh JC, Staehler M, Merchan JR, Xie R, Perini RF, Mody K, McKenzie J, Porta CG. Choueiri TK, et al. Among authors: eto m. Lancet Oncol. 2023 Mar;24(3):228-238. doi: 10.1016/S1470-2045(23)00049-9. Lancet Oncol. 2023. PMID: 36858721 Clinical Trial.
Highly immunogenic cancer cells require activation of the WNT pathway for immunological escape.
Takeuchi Y, Tanegashima T, Sato E, Irie T, Sai A, Itahashi K, Kumagai S, Tada Y, Togashi Y, Koyama S, Akbay EA, Karasaki T, Kataoka K, Funaki S, Shintani Y, Nagatomo I, Kida H, Ishii G, Miyoshi T, Aokage K, Kakimi K, Ogawa S, Okumura M, Eto M, Kumanogoh A, Tsuboi M, Nishikawa H. Takeuchi Y, et al. Among authors: eto m. Sci Immunol. 2021 Nov 12;6(65):eabc6424. doi: 10.1126/sciimmunol.abc6424. Epub 2021 Nov 12. Sci Immunol. 2021. PMID: 34767457
Reply by Authors.
Kobayashi S, Cho B, Mutaguchi J, Inokuchi J, Tatsugami K, Hashizume M, Eto M. Kobayashi S, et al. Among authors: eto m. J Urol. 2020 Jul;204(1):156. doi: 10.1097/JU.0000000000000709.02. Epub 2020 Apr 23. J Urol. 2020. PMID: 32324094 No abstract available.
Cancer du rein cliniquement localisé : quels sont les facteurs prédictifs du risque d'upstaging pathologique pT3a par invasion de la graisse ?
Bernhard J, Patard J, Bigot P, Suer E, Vuong N, Verhoest G, Alimi Q, Flamand V, Reix B, Beauval J, Benoit T, Nouhaud F, Lenormand C, Hamidi N, Eto M, Larre S, El Bakri A, Baco E, Ploussard G, Koutlidis N, Schneider A, Roupret M, Leon P, Carrouget J, Droupy S, Marchal S. Bernhard J, et al. Among authors: eto m. Prog Urol. 2015 Nov;25(13):800. doi: 10.1016/j.purol.2015.08.169. Prog Urol. 2015. PMID: 26544364 French. No abstract available.
Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study.
Grünwald V, Powles T, Kopyltsov E, Kozlov V, Alonso-Gordoa T, Eto M, Hutson T, Motzer R, Winquist E, Maroto P, Keam B, Procopio G, Wong S, Melichar B, Rolland F, Oya M, Rodriguez-Lopez K, Saito K, McKenzie J, Porta C. Grünwald V, et al. Among authors: eto m. Eur Urol Oncol. 2023 Aug;6(4):437-446. doi: 10.1016/j.euo.2023.01.010. Epub 2023 Jan 29. Eur Urol Oncol. 2023. PMID: 36720658 Free PMC article. Clinical Trial.
Comparison of therapeutic features and oncologic outcome in patients with pN1 prostate cancer among robot-assisted, laparoscopic, or open radical prostatectomy.
Kirisawa T, Shiota M, Kimura T, Edamura K, Miyake M, Morizane S, Yoshino T, Matsukawa A, Matsumoto R, Kasahara T, Nishiyama N, Eto M, Kitamura H, Nakamura E, Matsui Y; Japanese Urological Oncology Group. Kirisawa T, et al. Among authors: eto m. Int J Clin Oncol. 2023 Feb;28(2):306-313. doi: 10.1007/s10147-022-02278-7. Epub 2022 Dec 17. Int J Clin Oncol. 2023. PMID: 36527579
Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study.
Motzer R, Porta C, Alekseev B, Rha SY, Choueiri TK, Mendez-Vidal MJ, Hong SH, Kapoor A, Goh JC, Eto M, Bennett L, Wang J, Pan JJ, Saretsky TL, Perini RF, He CS, Mody K, Cella D. Motzer R, et al. Among authors: eto m. Lancet Oncol. 2022 Jun;23(6):768-780. doi: 10.1016/S1470-2045(22)00212-1. Epub 2022 Apr 27. Lancet Oncol. 2022. PMID: 35489363 Free PMC article. Clinical Trial.
969 results